Ultime notizie per Global X PropTech ETF (NASDAQ:PTEC)

Technology

Communication Services

Real Estate

Industrials

Consumer Cyclical

Financial Services

Other

The Fund invests at least 80 percent of its net assets, plus borrowings for investments purposes (if any), in the securities of the Global X PropTech Index (the Underlying Index), which may include common stocks, American Depositary Receipts (ADRs) and Global Depositary Receipts (GDRs) based on the securities in the Underlying Index. The Fund's 80 percent investment policy is non-fundamental and requires 60 days prior written notice to shareholders before it can be changed. The Underlying Index is owned and was developed by Global X Management Company LLC (the Index Provider), an affiliate of the Fund and the Fund's investment adviser (the Adviser). The Underlying Index is administered and calculated by Mirae Asset Global Indices Pvt. Ltd. (the Index Administrator), an affiliate of the Index Provider. The Underlying Index is designed to provide exposure to property technology (PropTech) companies that are positioned to benefit from technology that optimizes the way people buy, sell, rent, design, construct, manage, and research/market residential and commercial properties.

Guidewire Software,inc.

Ke Holdings Inc-Adr

Costar Group Inc.

Procore Tech Ser B Cvt Pfd

Airbnb Inc

Scout24 Se

Rea Group Ltd

Rightmove Plc

Rezi- Resideo Technologies Inc

Zillow Group, Inc., Class ''C''

Adt Inc.

Appfolio Inc Common Stock Usd 0.0001

Global X PropTech ETF

Hess Midstream LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HESM#NYSE">HESM</a>) ("HESM") today announced the commencement of an underwritten public offering of an aggregate of 15,022,517 Class A shares representing limited partner interests in HESM by an affiliate of Global Infrastructure Partners, a part of BlackRock (the "Selling Shareholder"). HESM will not receive any proceeds from the sale of Class A shares in the offering.
J.P. Morgan and Citigroup are acting as the joint bookrunning managers of the offering.
The offering of these securities is being made only by means of the prospectus supplement and accompanying base prospectus as filed with the Securities and Exchange Commission (the "SEC"). Copies of the preliminary prospectus supplement and accompanying base prospectus relating to the offering may be obtained free of charge on the SEC's website at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=54261726&amp;newsitemid=20250528740438&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=1&amp;md5=9d19ad294d441c628a09a58a6fd9fbf3">www.sec.gov</a> under HESM's name or from J.P. Morgan and Citigroup as follow

News

Offerings

HESM

Hess Midstream Announces An Underwritten Public Offering Of An Aggregate Of ~15.022M Class A Shares

NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) reported quarterly earnings of $0.81 per share which missed the analyst consensus estimate of $0.88 by 7.95 percent. This is a 32.35 percent increase over earnings of $0.61 per share from the same period last year. The company reported quarterly sales of $44.06 billion which beat the analyst consensus estimate of $43.21 billion by 1.97 percent. This is a 69.18 percent increase over sales of $26.04 billion the same period last year.

Earnings

Earnings Beats

Earnings Misses

Macro Notification

General

NVDA

NVIDIA Q1 Adj. EPS $0.81 Misses $0.88 Estimate, Sales $44.06B Beat $43.21B Estimate

SentinelOne Q1 Adj. EPS $(0.02) Misses $0.02 Estimate, Sales $229.03M Beat $228.35M Estimate

WIIM

HP shares are trading lower after the company reported worse-than-expected Q2 adjusted EPS results and issued Q3 adjusted EPS guidance below estimates.

USPH

U.S. Physical Therapy Listed On NYSE Texas

HP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) lowers FY2025 GAAP EPS guidance from $2.86-$3.16 to $2.32-$2.62 vs $3.14 analyst estimate..

Guidance

HP Lowers FY2025 GAAP EPS Guidance from $2.86-$3.16 to $2.32-$2.62 vs $3.14 Est

Ncino (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNO#NASDAQ">NCNO</a>) is looking for Q2 Adj EPS of $0.13-0.14 vs $0.15 analyst estimate. seessales of $142.000 million-144.000 million vs $143.36 million estimate.

NCNO

Ncino Sees Q2 Adj EPS $0.13-0.14 vs $0.15 Est; Sees Sales $142.000M-144.000M vs $143.36M Est

HP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) is looking for Q3 GAAP EPS of $0.57-$0.69 vs $0.89 analyst estimate..

HP Sees Q3 GAAP EPS $0.57-$0.69 vs $0.89 Est

HP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) lowers FY2025 Adj EPS guidance from $3.45-$3.75 to $3.00-$3.30 vs $3.49 analyst estimate..

HP Lowers FY2025 Adj EPS Guidance from $3.45-$3.75 to $3.00-$3.30 vs $3.49 Est

HP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) is looking for Q3 Adj EPS of $0.68-$0.80 vs $0.90 analyst estimate..

HP Sees Q3 Adj EPS $0.68-$0.80 vs $0.90 Est

SNWV

Sanuwave Health Included In Russell 2000 Index

Financing led by SR One and includes participation from new and existing investors, including Point72, Viking Global Investors, Venrock Healthcare Capital Partners, New Enterprise Associates (NEA), Nextech, Vivo Capital, and NEXTBio Capital
Pro forma cash and investments expected to fund current operating plan into the second half of 2027 and through anticipated primary endpoint readout from first ORIC-944 Phase 3 registrational trial in prostate cancer
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORIC#NASDAQ">ORIC</a>), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that it has agreed to sell approximately 19.2 million shares of its common stock (or pre-funded warrants in lieu thereof) to a select group of institutional and accredited healthcare specialist investors in a private placement, at a price per share of $6.50 (or $6.4999 per pre-funded warrant), representing a premium of approximately 18% to ORIC's 10-day trailing volume-weighted average price as of deal signing on May 23, 2025. The pre-funded warrants will have an exercise price of $0.0001 per share of common stock, will be immediately exercisable, and will remain exercisable until exercised in full. The financing is expected to close on May 29, 2025, subject to customary closing conditions. ORIC anticipates the gross proceeds from the private placement to be approximately $125 million, before deducting any offering related expenses.
The financing includes participation from new and existing institutional investors and is being led by SR One, with participation from Point72, Viking Global Investors, Venrock Healthcare Capital Partners, NEA, Nextech, Vivo Capital, and NEXTBio Capital.
ORIC intends to use the net proceeds from the proposed financing to fund research and development of its clinical-stage product candidates and research programs and for working capital and general corporate purposes. The proceeds from this financing, combined with current cash, cash equivalents and marketable securities, is expected to be sufficient to fund the current operating plan into the second half of 2027 and through the anticipated primary endpoint readout from the first ORIC-944 Phase 3 registrational trial in prostate cancer.

ORIC

ORIC Pharma Announces $125M Private Placement At 18% Premium

Ooma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OOMA#NYSE">OOMA</a>) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.18 by 11.11 percent. This is a 42.86 percent increase over earnings of $0.14 per share from the same period last year. The company reported quarterly sales of $65.00 million which beat the analyst consensus estimate of $64.82 million by 0.28 percent. This is a 4.00 percent increase over sales of $62.50 million the same period last year.

OOMA

Ooma Q1 Adj. EPS $0.20 Beats $0.18 Estimate, Sales $65.00M Beat $64.82M Estimate

Federal National Mortgage Association (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/FNMA#OTCQB">FNMA</a>), aka Fannie Mae, shares were trading up 2.09% to $10.77 Wednesday afternoon following an announcement and a statement from President Donald Trump.
What to Know: Shares gained Wednesday after Trump said he was working on taking the housing giants (including Freddie Mac) public, while clarifying that the U.S. Government would retain its implicit guarantees.
Trump, in a Truth Social <a href="https://truthsocial.com/@realDonaldTrump/posts/114582141732207441">post</a> late Tuesday, expressed his intent to &#8220;TAKE THESE AMAZING COMPANIES PUBLIC&#8221; and emphasized his continued oversight as president.
Separately, Fannie Mae announced the <a href="https://www.fanniemae.com/newsroom/fannie-mae-news/fannie-mae-launches-ai-fraud-detection-technology-partnership-palantir">launch</a> of its AI-powered Crime Detection Unit in partnership with Palantir Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>). This collaboration is set to enhance Fannie Mae&#8217;s fraud detection capabilities using leading AI-enabled financial crimes data science. 
The company believes this new platform will detect and prevent mortgage fraud with unprecedented speed and precision, ultimately saving the U.S. housing market millions in future losses. 
Fannie Mae Chairman William J. Pulte <a href="https://www.fanniemae.com/newsroom/fannie-mae-news/fannie-mae-launches-ai-fraud-detection-technology-partnership-palantir">stated</a>, &#8220;In partnership with Palantir, Fannie Mae's Crime Detection Unit will increase safety and soundness by rooting out bad actors in our housing system.&#8221; Palantir's CEO Alex Karp called the partnership a &#8220;revolution in how we combat mortgage fraud in this country.&#8221;
Read Also: <a href="https://www.benzinga.com/news/25/05/45648088/coreweave-crwv-stock-pulls-back-from-all-time-high-whats-driving-the-volatility">CoreWeave Stock Pulls Back From All-Time High: What&#8217;s Driving The Volatility?</a>
<h1 class="wp-block-heading">How To Buy FNMA Stock</h1>
Besides going to a brokerage platform to purchase a share — or fractional share — of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
For example, for Federal National Mortgage, it is in the Financials sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, FNMA has a 52-week high of $11.91 and a 52-week low of $1.02.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/05/45654518/federal-reserve-minutes-flag-tariff-driven-inflation-eye-us-market-volatility-as-economic-risk">Federal Reserve Minutes Flag Tariff-Driven Inflation, Eye US Market Volatility As Economic Risk</a></li>
</ul>
Photo: Shutterstock

FNMA

PLTR

Fannie Mae Stock Jumps On Trump Privatization, Palantir Technologies AI Fraud Unit

XELB

Xcel Brands Receives Nasdaq Letter Regarding Delinquent Form 10-k And Form 10-q Filing

POWW

Outdoor Holding Company shares are trading higher after the company announced changes to its CEO and chairman roles.

HP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) reported quarterly earnings of $0.71 per share which missed the analyst consensus estimate of $0.80 by 11.25 percent. This is a 13.41 percent decrease over earnings of $0.82 per share from the same period last year. The company reported quarterly sales of $13.22 billion which beat the analyst consensus estimate of $13.15 billion by 0.53 percent. This is a 3.28 percent increase over sales of $12.80 billion the same period last year.

HP Q2 Adj. EPS $0.71 Misses $0.80 Estimate, Sales $13.22B Beat $13.15B Estimate

Pure Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSTG#NYSE">PSTG</a>) sees Q2 sales of $845.000 million vs $841.78 million analyst estimate.

PSTG

Pure Storage Sees Q2 Sales $845.000M vs $841.78M Est

Viper Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNOM#NASDAQ">VNOM</a>) has outperformed the market over the past 5 years by 15.52% on an annualized basis producing an average annual return of 29.3%. Currently, Viper Energy has a market capitalization of $5.29 billion. 
Buying $1000 In VNOM: If an investor had bought $1000 of VNOM stock 5 years ago, it would be worth $3,823.70 today based on a price of $40.34 for VNOM at the time of writing.
<h3>Viper Energy's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748463328_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

VNOM

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

Broad and deep PSA responses achieved, with 59% PSA50 response rate (confirmed rate of 47%, and one additional response pending confirmation) and 24% PSA90 response rate (all confirmed) in patients with mCRPC&nbsp; &nbsp; &nbsp;&nbsp;
PSA responses were observed across all ORIC-944 dose levels and at comparable rates in combination with apalutamide and with darolutamide; majority of patients are still ongoing with multiple patients approaching one year or more
Both combination regimens demonstrated a safety profile compatible with long term dosing, with the vast majority of adverse events Grade 1 or 2
Announced concurrent $125 million financing, which extends cash runway into 2H 2027 and through anticipated primary endpoint readout from first Phase 3 trial
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORIC#NASDAQ">ORIC</a>), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced potentially best-in-class preliminary efficacy and safety data from the ongoing Phase 1b trial of once daily ORIC-944 in combination with androgen receptor (AR) inhibitors in patients with metastatic castration-resistant prostate cancer (mCRPC).

ORIC Pharma Announces Preliminary Efficacy And Safety Data From Ongoing Phase 1b Trial Of Once Daily ORIC-944 In Combination With AR Inhibitors In Patients With mCRPC

Comments

Global X PropTech ETF

Notizie

Ultime notizie per Global X PropTech ETF (NASDAQ:PTEC)

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO